Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.23 EUR 2.76% Market Closed
Market Cap: 103.9m EUR
Have any thoughts about
Heidelberg Pharma AG?
Write Note

Relative Value

The Relative Value of one HPHA stock under the Base Case scenario is 2.71 EUR. Compared to the current market price of 2.23 EUR, Heidelberg Pharma AG is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HPHA Relative Value
Base Case
2.71 EUR
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
77
vs Industry
39
Median 3Y
14.5
Median 5Y
15.1
Industry
7.7
Forward
10.2
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-8.4
Industry
22.7
Forward
-5.1
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-8.7
Industry
21.6
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-10.3
Industry
25.2
vs History
76
vs Industry
34
Median 3Y
3.1
Median 5Y
3.4
Industry
2.5
vs History
76
vs Industry
38
Median 3Y
11.9
Median 5Y
12.3
Industry
7.7
Forward
8.7
vs History
66
vs Industry
31
Median 3Y
14.4
Median 5Y
16.3
Industry
9
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-8.3
Industry
4.2
Forward
-4.1
vs History
vs Industry
Median 3Y
-7
Median 5Y
-7.9
Industry
4.1
Forward
-2.9
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-8.4
Industry
5.7
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-7.8
Industry
3.6
vs History
98
vs Industry
34
Median 3Y
7.6
Median 5Y
9
Industry
4.6

Multiples Across Competitors

HPHA Competitors Multiples
Heidelberg Pharma AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Heidelberg Pharma AG
XETRA:HPHA
103.9m EUR 12.3 -5.5 -4.5 -4.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average P/E: 208.3
Negative Multiple: -5.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average EV/EBITDA: 17.2
Negative Multiple: -4.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average EV/EBIT: 22.5
Negative Multiple: -4.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top